Pricing Log in Create free account
Saturday 17 October 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.

499.39 9.36 −1.84%
Market cap
$129.0B
P/E
28.8×
Fwd P/E
25.5×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Vertex Pharmaceuticals Incorporated (VRTX) P/B ratio

Alert me on P/B ratio

As of 16 October 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/B ratio of 6.3×. Over the past ten years it has ranged from 4.8× (October 2021) to 32.6× (April 2015); the current reading is higher than 29% of that period. That is above the Biotechnology industry median of 2.1× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 6.2× (1.87%)
FY2024 6.3× 5.08%
FY2023 6.0× 14.40%
FY2022 5.3× (6.03%)
FY2021 5.6× (20.73%)
FY2020 7.1× (23.47%)
FY2019 9.2× (2.79%)
FY2018 9.5× (49.01%)
FY2017 18.6× 36.07%
FY2016 13.7× (50.68%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 6.2× 6.20%
Mar 2026 5.9× (5.64%)
Dec 2025 6.2× 7.45%
Sep 2025 5.8× (13.13%)
42 more quarters

Against its own ten years

Low 4.8× High 32.6×
Ten-year median 8.4×
Current reading's percentile 31

P/B ratio against peers

Company P/B ratio
REGN Regeneron Pharmaceuticals, Inc. compare 2.6×
RPRX Royalty Pharma PLC compare 2.8×
ROIV Roivant Sciences Ltd. compare 4.9×
ARGX argenex SE compare 6.1×
VRTX Vertex Pharmaceuticals Incorporated 6.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 8.0×
MRNA Moderna, Inc. compare 12.8×
RVMD Revolution Medicines, Inc. compare 14.4×
ALNY Alnylam Pharmaceuticals, Inc. compare 22.9×
Biotechnology industry median 2.1×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on VRTX